Summary
This 8-K filing from Pfizer Inc. (PFE), dated April 20, 2004, announces the company's financial results for the first quarter of 2004. The report primarily serves to furnish a press release detailing these results, which is included as an exhibit. Investors should review the press release for specific performance metrics, revenue figures, and any commentary from management on the company's operational and financial condition during the quarter. The core of this filing is the Q1 2004 earnings announcement. While the 8-K itself is a formal notification of the press release, the press release itself contains the substance of Pfizer's performance. Investors seeking to understand Pfizer's trajectory and immediate financial health should consult the provided press release for details on sales, profitability, and any forward-looking statements or strategic updates made by the company.
Key Highlights
- 1Pfizer Inc. (PFE) filed an 8-K report on April 20, 2004.
- 2The filing's primary purpose is to announce Pfizer's financial results for the first quarter of 2004.
- 3A press release containing the Q1 2004 financial results is furnished as Exhibit 99.
- 4The press release is incorporated by reference into the 8-K filing.
- 5The report confirms the event date for these results was April 19, 2004.
- 6No specific financial figures are detailed within the 8-K text itself, as they are contained in the referenced press release.